ClinicalTrials.gg
Not yet recruitingNCT06463678Updated Nov 4, 2026

Trial to Evaluate the Efficacy And Safety of IVIEW-1201 In the Treatment of Fungal Keratitis

A Phase 2 interventional study of IVIEW-1201 and NATACYN® in Fungal Keratitis, sponsored by IVIEW Therapeutics Inc.. Not yet recruiting. Open to participants aged 15 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by IVIEW Therapeutics Inc. · Phase 2, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
15 Years and older
Sex
All
01

Study summary

A Phase II, Multi-center, Randomized, Masked, Parallel-Control Study to Evaluate the Clinical Efficacy and Safety of IVIEW-1201 (1.0% PVP-Iodine) Gel Forming Ophthalmic Solution in the Treatment of Fungal Keratitis.

02

Conditions studied

  • Fungal Keratitis

Browse trials for

03

In context

Keratitis

108 studies on the registry are indexed under Keratitis; 19 are open to participants now.

This study's planned enrollment of 60 is above the median of 40 across 70 interventional studies indexed under Keratitis.

Browse Keratitis studies →

Lead sponsor

IVIEW Therapeutics Inc. is the lead sponsor of 7 studies on the registry; 2 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Volunteered to participate in the study and signed the Form after receiving a verbal and written explanation of this clinical trial. In cases where the subject is unable to sign the Informed Consent Form, his/her guardian may sign in accordance with relevant regulations.
  2. Aged above 15 (inclusive), male or female.
  3. Preliminary diagnosis of fungal keratitis based on medical history and clinical observations: corneal focus score ≥ 1.
  4. Fungal infection confirmed by laboratory tests (positive for any of the three: fungal hyphae on scraping examination, fungal hyphae on confocal microscopy, positive fungal culture).
  5. Not treated with antifungal drugs within 48 hours.
  6. Willing to cooperate in the completion of all procedures and visits required for the trial.

Exclusion criteria

Exclusion Criteria:

  1. Patients with systemic or ocular diseases, or functional disorders with comorbidities, or structural abnormalities that, in the judgment of the investigator, could adversely affect the course or results of the trial (e.g., hyperthyroidism, hepatitis, acute and chronic renal insufficiency).
  2. Those who have a history of allergy or serious adverse reactions to any component of IVIEW-1201 and NATACYN®; a history of allergy or serious adverse reactions to polyene macrolides and other antifungal drugs; or have a cumulative total of three or more allergies to other drugs, food and environment; or have a predisposition to allergic symptoms such as rash or urticaria.
  3. Patients with severe cardiac, pulmonary, hepatic, or renal dysfunction and patients with life-threatening or severe unstable underlying diseases.
  4. Those with other combined infectious ocular surface diseases.
  5. Those with sclera involvement.
  6. Those with combined corneal perforation or imminent perforation.
  7. Patients with glaucoma and corneal limbal stem cell abnormalities that cannot be cured at the same time, severe chemical burns of cornea and conjunctiva, corneal foreign bodies and other diseases not suitable for this trial.
  8. Those who would need to wear corneal contact lenses during the trial.
  9. Those who add other medications to treat fungal infections during the trial (except non-facial local treatment).
  10. Those who are using other drugs that may interfere with the efficacy or safety evaluation of IVIEW-1201.
  11. Systemic use of antifungal drugs within 14 days prior to screening.
  12. Systemic use of steroidal drugs within 14 days prior to screening. Local use of eye steroidal drugs or nonsteroidal anti-inflammatory drugs (NSAIDs) within 3 days before enrollment (nasally or bronchially inhaled steroidal drugs are not allowed at any time during the trial).
  13. Participation in other interventional clinical trials within 30 days prior to the trial.
  14. Pregnant or lactating women, women with positive blood or urine pregnancy tests and those planning to become pregnant (including male subjects); subjects who did not take effective measures within 1 month before enrollment, or subjects (including male subjects) who are unwilling to take effective contraceptive measures within the next 6 months.
  15. Other conditions or illnesses judged by the clinical investigator to be unsuitable for enrollment.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    IVIEW-1201

    Drug: IVIEW-1201

  • Active comparator
    NATACYN®

    Drug: NATACYN®

Interventions

  • Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.

    Also known as: Treatment Arm

  • DrugNatamycinStudies of NatamycinNatamycin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Shake well before use and administer 1 drop into the conjunctival sac every 1 hour on Day 1, 2 and 3 when awake; every 2 hours on Day 4-14 when awake; 6 times a day on Day 15-21 with a dosing interval of at least 2.5 hours; 4 times a day on Day 22-28 with a dosing interval of at least 3 hours. The time course of administration is 28 days. After 14 days of dosing, if a patient reaches the primary and secondary endpoints, the investigational drug can be discontinued at the discretion of the investigator.

    Also known as: Active Comparator Arm

06

What researchers measure

Primary outcomes

  1. Clinical cure rate

    Proportion of subjects with a score of 0/12. This is manifested by the resolution of clinical symptoms, healing of corneal ulcers, negative fluorescein staining, corneal recovery to translucency or transparency, and resolution of hypopyon.

    Time frame: Day 29 ± 1 day

Secondary outcomes

  1. Fungal clearance

    Positive if fungal hyphae are visible on smear microscopy or confocal microscopy at baseline and negative if no fungal hyphae are visible on smear microscopy or confocal microscopy at the last visit.

    Time frame: Day 29 ± 1 day

  2. Best-corrected visual acuity

    The best-corrected visual acuity and its distribution ratio with 0.3, 0.6 and 1.0 LogMAR as cut-offs of test eyes in the test and control groups at baseline and at the last visit. A stratified analysis is carried out to calculate the change in best-corrected visual acuity.

    Time frame: Baseline (Day 1) and Day 29 ± 1 day

07

Study locations

No study locations are listed for this record.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Dec 2027; primary completion for Dec 2028, 12 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Aug 2026 → Dec 2027, primary completion Dec 2027 → Dec 2028 and completion Dec 2027 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2024
First posted
Jun 18, 2024
StartEst.
Dec 1, 2027was Aug 2026
Primary completionEst.
Dec 31, 2028was Dec 2027
CompletionEst.
Dec 31, 2029was Dec 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Aug 1, 2026→Dec 1, 2027
Nov 4, 2026
Primary completion
Dec 31, 2027→Dec 31, 2028
Nov 4, 2026
Study completion
Dec 31, 2027→Dec 31, 2029
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    Start date Aug 1, 2026→Dec 1, 2027
    Primary completion Dec 31, 2027→Dec 31, 2028
    Study completion Dec 31, 2027→Dec 31, 2029
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06463678
Lead sponsor
IVIEW Therapeutics Inc.
Responsible party
Sponsor
First posted
Jun 18, 2024
Start date
Dec 1, 2027 (estimated)
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Nov 4, 2026

Study contacts

Bo Liang, PhD
Contact
bliang@iviewinc.com
609 773 8580

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IVIEW-1201

Start the discussion